VA
PRQR icon

Verdad Advisers’s ProQR Therapeutics PRQR Stock Holding History

Verdad Advisers’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35.5K Buy
+19,100
New +$31.4K 0.03% 204

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Verdad Advisers's PRQR Position: Q2 2026 in Review

Verdad Advisers opened a new position in ProQR Therapeutics (PRQR) in Q2 2026: 19,100 shares worth $35.5K. The stake represents 0.03% of the portfolio and ranks #204 among its holdings.

70 funds tracked by Wall St. Rank hold PRQR as of Q2 2026.

  • Verdad Advisers held 19,100 shares of ProQR Therapeutics worth $35.5K as of Q2 2026.
  • ProQR Therapeutics was a new Verdad Advisers position in Q2 2026.
  • ProQR Therapeutics made up 0.03% of Verdad Advisers's portfolio in Q2 2026, its #204 holding.
  • 70 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2026.

Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.